eli lilly retatrutide trial sign up Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Eli Lilly's triple agonist retatrutide

Tirzepatide slows gastric emptying

Common biologic pathway Doctors are taught that "if a patient has an addiction to substance A, you give them the antidote for substance A, such as a nicotine patch for tobacco, or naltrexone for alcohol," Al-Aly said

You can read more about our medical team by visiting the medical team page or learn more about how we curate content by visiting our editorial process

[DOI] [PubMed] [Google Scholar] 11.National Kidney Foundation

GLP-1 medications don't require a special amount of water, but they quietly cut your water consumption if you're not paying attention: they blunt appetite and thirst cues, slow how fast your stomach empties so you feel full sooner, and can cause fluid loss through nausea or diarrhea